Department of Urology, University of Tsukuba, Tsukuba, Japan.
Department of Urology, Aichi Cancer Center, Nagoya, Japan.
Int J Urol. 2022 Nov;29(11):1331-1337. doi: 10.1111/iju.14996. Epub 2022 Aug 17.
To identify the clinicopathological features of adrenal malignancies and analyze the prognoses of patients with adrenal cortical carcinoma (ACC) and malignant pheochromocytoma (MPCC).
We used a hospital-based cancer registry data in Japan to extract cases of adrenal malignancies that were histologically confirmed, diagnosed, and initially treated from 2012-2015. For survival analysis, we used data from the 2008-2009 cohort to estimate 5-year overall survival (OS) by the Kaplan-Meier method.
A total of 989 adrenal malignancies were identified in the 2012-2015 cohort. The most common histologies were ACC (26.4%), diffuse large B-cell lymphoma (DLBCL; 25.4%), neuroblastoma (22.2%), and MPCC (11.9%). While most ACC and MPCC patients were in their 60s, DLBCL patients accounted for 61.5% of adrenal malignancies in the over-70 cohort. Among ACC patients with clinical staging data, 46.3% of patients were stage IV. Although surgery was a chief strategy for all stages, younger patients tended to receive combination therapy, including surgery and chemotherapy or hormone therapy. In the 2008-2009 cohort, the 5-year OS rates of ACC (n = 49) and MPCC (n = 23) patients were 56.2% and 86.4% while ACC patients without surgery had 1- and 2-year OS rates of 25.0% and 12.5%.
In Japan, DLBCL accounted for the majority of adrenal malignancies in older patients. Despite advanced staging, ACC patients were mainly treated with surgery and their prognosis was not satisfactory. Such epidemiological data may be useful in considering initial management strategies.
确定肾上腺恶性肿瘤的临床病理特征,并分析肾上腺皮质癌(ACC)和恶性嗜铬细胞瘤(MPCC)患者的预后。
我们使用日本基于医院的癌症登记数据,从 2012-2015 年提取经组织学证实、诊断和初步治疗的肾上腺恶性肿瘤病例。为了进行生存分析,我们使用 2008-2009 队列的数据,通过 Kaplan-Meier 方法估计 5 年总生存率(OS)。
在 2012-2015 年队列中,共发现 989 例肾上腺恶性肿瘤。最常见的组织学类型是 ACC(26.4%)、弥漫性大 B 细胞淋巴瘤(DLBCL;25.4%)、神经母细胞瘤(22.2%)和 MPCC(11.9%)。虽然大多数 ACC 和 MPCC 患者在 60 多岁,但 DLBCL 患者在 70 岁以上的肾上腺恶性肿瘤患者中占 61.5%。在有临床分期数据的 ACC 患者中,46.3%的患者为 IV 期。尽管手术是所有分期的主要策略,但年轻患者更倾向于接受包括手术、化疗或激素治疗在内的联合治疗。在 2008-2009 年队列中,ACC(n=49)和 MPCC(n=23)患者的 5 年 OS 率分别为 56.2%和 86.4%,而未接受手术的 ACC 患者的 1 年和 2 年 OS 率分别为 25.0%和 12.5%。
在日本,DLBCL 占老年患者肾上腺恶性肿瘤的大部分。尽管分期较晚,ACC 患者主要接受手术治疗,但其预后并不理想。这些流行病学数据可能有助于考虑初始治疗策略。